September 30, 2016
Daiichi Sankyo said on September 28 that it has concluded a cross-licensing agreement and collaboration agreement with Canadian biotech Zymeworks to develop proprietary cancer immuno-oncology products. Zymeworks boasts bispecific antibody and protein engineering technology platforms that could be applied to...read more